Mira Pharmaceuticals (Mira Pharmaceuticals) Short-Term Capital Lease Obligation : $0.01 Mil (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Mira Pharmaceuticals Short-Term Capital Lease Obligation?

Mira Pharmaceuticals's Short-Term Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.01 Mil.

Mira Pharmaceuticals's quarterly Short-Term Capital Lease Obligation declined from Jun. 2023 ($0.08 Mil) to Sep. 2023 ($0.07 Mil) and declined from Sep. 2023 ($0.07 Mil) to Dec. 2023 ($0.01 Mil).

Mira Pharmaceuticals's annual Short-Term Capital Lease Obligation increased from Dec. 2021 ($0.00 Mil) to Dec. 2022 ($0.27 Mil) but then declined from Dec. 2022 ($0.27 Mil) to Dec. 2023 ($0.01 Mil).

Mira Pharmaceuticals Short-Term Capital Lease Obligation Historical Data

The historical data trend for Mira Pharmaceuticals's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mira Pharmaceuticals Short-Term Capital Lease Obligation Chart

Mira Pharmaceuticals Annual Data

Trend

Dec21

Dec22

Dec23

Short-Term Capital Lease Obligation

0.27

0.01

Mira Pharmaceuticals Quarterly Data
	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Short-Term Capital Lease Obligation	Get a 7-Day Free Trial				0.27	0.07	0.08	0.07	0.01

Mira Pharmaceuticals Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.

Mira Pharmaceuticals Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Mira Pharmaceuticals's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Mira Pharmaceuticals (Mira Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mira Pharmaceuticals Inc (NAS:MIRA) » Definitions » Short-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

K6S:Germany

Address

855 N Wolfe Street, Suite 601, Baltimore, MD, USA, 21205

Website

https://www.mirapharmaceuticals.com

Mira Pharmaceuticals Inc is an early pre-clinical-stage pharmaceutical company focused on the development and commercialization of a new molecular synthetic THC analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. Its target patient population is also typically presenting with chronic pain. its drug candidate, MIRA1a, if approved by the FDA, maybe a significant advancement in the treatment of neuropsychiatric, inflammatory, and neurologic diseases and disorders. Based on pre-clinical and animal studies conducted by the company, it believes that MIRA1a enhances the therapeutic potential for treating anxiety, cognitive decline and chronic pain.

Executives

Brian Patrick Mcnulty	10 percent owner	C/O MIRA PHARMACEUTICALS, INC., 900 WEST PLATT STREET, SUITE 200, TAMPA FL 33606-2173
Brian Frederick Daly	director	C/O MIRA PHARMACEUTICALS, INC., 900 WEST PLATT STREET, SUITE 200, TAMPA FL 33606-2173
George Cappy	10 percent owner	C/O MIRA PHARMACEUTICALS, INC., 900 WEST PLATT STREET, SUITE 200, TAMPA FL 33606-2173
David C Vorhoff	director	C/O STAR SCIENTIFIC, INC., 801 LIBERTY WAY, CHESTER VA 23836
Chapman Christopher C Jr	director, officer: Executive Chairman	C/O STAR SCIENTIFIC, INC., 7475 WISCONSIN AVENUE, SUITE 850, BETHESDA MD 20814
Adam Kaplin	officer: Pres. & Chief Scientific Off.	C/O AKERS BIOSCIENCES, INC., 1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK NY 10036
Michelle Yanez	officer: CFO, Secretary & Treasurer	449 S. 12TH STREET UNIT 1705, TAMPA FL 33602
Hugh Iii Mccoll	director	100 RIVER BLUFF DRIVE, SUITE 210, LITTLE ROCK AR 72202
Christos Nicholoudis	director	C/O MIRA PHARMACEUTICALS, INC., 900 WEST PLATT STREET, SUITE 200, TAMPA FL 33606-2173
Bradley Kroenig	director	C/O MIRA PHARMACEUTICALS, INC., 900 WEST PLATT STREET, SUITE 200, TAMPA FL 33606-2173
Erez Aminov	director, officer: Chief Executive Officer	C/O MIRA PHARMACEUTICALS, INC., 900 WEST PLATT STREET, SUITE 200, TAMPA FL 33606-2173
Talhia Tuck	director	C/O MIRA PHARMACEUTICALS, INC., 900 WEST PLATT STREET, SUITE 200, TAMPA FL 33606-2173
Bay Shore Trust	10 percent owner	C/O MIRA PHARMACEUTICALS, INC., 900 WEST PLATT STREET, SUITE 200, TAMPA FL 33606-2173